Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…Abstract Number: 1804 • ACR Convergence 2023
Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women
Background/Purpose: Plant-based diets are growing in popularity due to their health benefits for selected cardiometabolic diseases as well as favorable environmental impact. However, the limited…Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…Abstract Number: 1888 • ACR Convergence 2023
Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy
Background/Purpose: In a recent study, the low specificity of Dual-Energy CT (DECT) has raised concerns due to the frequent occurrence of pseudo lesions, also referred…Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…Abstract Number: 0753 • ACR Convergence 2023
Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…Abstract Number: 1909 • ACR Convergence 2023
Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…Abstract Number: 0238 • ACR Convergence 2023
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
- 1
- 2
- 3
- …
- 40
- Next Page »